Improved antibody targeting with interferon-α-2b conjugate

Journal of Immunotherapy

Volumn 20, Issue 3, 1997, Pages 194-201

  Thakur, M L ^a   Li, J ^a   Donegan, M ^a   Pallela, V R ^a   Kolan, H ^a   Duggaraju, R ^a   Maish, D ^a   Srivastava, S ^b  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

Biological response modifiers; Immunoconjugate; Interferon 2b; Tc 99m mAb; Tumor uptake of Tc 99m mAb, improving

Indexed keywords

ALPHA2B INTERFERON; ANTIBODY CONJUGATE; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN F(AB')2 FRAGMENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ME 31 3; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG CONJUGATION; DRUG TARGETING; DRUG UPTAKE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MELANOMA; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; HUMANS; IMMUNOCONJUGATES; INTERFERON ALFA-2B; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM PROTEINS; RADIOIMMUNOTHERAPY; TUMOR CELLS, CULTURED;

EID: 0031463669     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199705000-00004     Document Type: Article

References (47)

1. McAfee JG. Radiopharmaceuticals for medical imaging. Radiology 1989;171:593-601.
2. Goldenberg DM. Targeting concerns with radiolabeled antibodies. Arch Pathol Lab Med 1988;112:580-7.
3. Carasquillo JA, Bunn PA, Keenan AM, et al. Radioimmunodetection of cutaneous T-cell lymphoma with In-111 T 101 monoclonal antibodies. N Engl J Med 1986;315:673-80.
4. Dykes PW, Bradwell AR, Chapman CE, Vaughan AT. Radioimmunotherapy of cancer: clinical studies with limiting factors. Cancer Treat Rev 1987;14:87-106.
5. Fazio F, Paganelli G. Antibody-guided scintigraphy: targeting of the magic bullet. Eur J Nucl Med 1993;20:1138-40.
6. 2 fragment to subcutaneous human glioma xenografts using local hyperthermia. Cancer Res 1990;50:1803-9.
7. Goodwin DA. Pharmacokinetics and antibodies [Editorial]. J Nucl Med 1987;28:1358-62.
8. Sands H, Shah S, Gallagher BM. Vascular volume and permeability of human and murine tumors grown in athymic mice. Cancer Lett 1985;27:15-21.
9. Sands H, Jones PL, Shah SA, Palme D, Vessella RL, Gallagher BM. Correlation of vascular permeability and blood flow with monoclonal antibody uptake by a human Clouser and renal cell xenografts. Cancer Res 1988;48:188-92.
10. 2 fragments against CEA studied in human tumour xenograft model. Br J Cancer 1986;54:341-4.
11. Carrasquillo JA, Abrams PG, Schroff RW, et al. Effect of antibody dose on the imaging and biodistribution of indium-111 9.2.27 anti-melanoma monoclonal antibody. J Nucl Med 1988:29:39-47.
12. Colcher D, Esteban J, Carrasquillo JA, et al. Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Res 1987;47:4218-24.
13. Carrasquillo JA, Mulshine JL, Brun Jr, et al. Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma. J Nucl Med 1987;28:281-7.
14. Murray JL, Rosenblum MG, Lamki L. et al. Clinical parameters related to optimal tumor localization of indium-111-labeled antimelanoma monoclonal antibody ZME-018. J Nucl Med 1987;28:25-33.
15. Halpern SE, Dillman RO, Witztum KF, et al. Radioimmunodetection of melanoma utilizing In-111 96.5 monoclonal antibody: a preliminary report. Radiology 1985;155:493-9.
16. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of MAb percolation through tumors: a binding site barrier. J Nucl Med 1990;31:1191-8.
17. Stickney DR, Gridley DS, Kirk GA, Stater JM. Enhancement of monoclonal antibody binding to melanoma with single dose mediation or hyperthermia. Natl Cancer Inst Monogr 1987; 3:47-52.
18. Cope DA, Dewhirst MW, Friedman HS. Bigner DD, Zalutsky MR. Enhanced delivery of a monoclonal antibody F(ab')2 fragment to subcutaneous human glioma xenografts using local hyperthermia. Cancer Res 1990;50:1803-9.
19. Hnatowich DJ, Virzi F, Ruskovski M. Investigations of avidin and biotin for imaging applications. J Nucl Med 1987; 28:1294-302.
20. Li J, Merton DA Thakur ML, et al. Influence of biological response modifiers: measurements of tumor blood flow and temperature. J Immunother 1994;16:175-80.
21. Staren ED, Essner R, Economou JS, et al. Overview of biological response modifiers. Semin Surg Oncol 1989;5:379-84.
22. Vilcek J, DeMaeyer E. Interferon. In: Finter NB. ed. Interferons and the immune system. Amsterdam: Elsevier Science Publishers. 1984:268.
23. Hooks JJ, Detrick B. Immunoregulatory functions of interferon. In: Torrence PF, ed. Biological response modifiers. New York: Academic Press, 1985:57-75.
24. Balmer CM. Clinical use of biological response modifiers in cancer treatment DICP. Ann Pharmacother 1990;24:761-7.
25. Wimer BM. The ideal biological response modifier. Mol Biother 1989;1:311-7.
26. Garbe C, Krasagakis K, Zouboulis C. et al. Gamma and their combinations of human melanoma cells in vitro: changes of proliferation, melanin synthesis and immunophenotype. J Invest Dermatol 1990;95:213-37S.
27. 2-microglobulin on cultured human melanoma cells by interferon. JNCI 1982;68:19-25.
28. Kuhn JA, Beatty BG, Wong JYC, et al. Interferon enhancement of radioimmunotherapy for colon carcinoma. Cancer Res 1991;51:2335-9.
29. 131I-CC49) given in combination with γ-interferon. Cancer Res 1993;53:600-8.
30. Rowlinson G, Balkwill F, Snook G, Hooker G, Epenetos AA. Enhancement by γ-interferon of in vivo tumor radiolocalization by a monoclonal antibody against HLA-DR antigen. Cancer Res 1986;46:6413-7.
31. Rosenblum MG, Lamki LM, Murray JL, Carlo DJ, Gutterman JV. Interferon induced changes in pharmacokinetics and tumor uptake of In-111 labeled antimelanoma antibody 96.5 in melanoma patients. J Natl Cancer Inst 1988;80:160-5.
32. Li J, Merton D, Duggaraju R, Thakur ML. Augmenting tumor uptake of anti-melanoma antibody MEM 136: influence of interferon. Nucl Med Biol 1996;23:873-879.
33. Li J, Duggaraju R, Maish DR, Thakur ML. Effect of interferon-α-2b on the enhancement of tumor uptake of Tc-99m labeled monoclonal antibodies. Nucl Med Commun 1996;17:346-52.
34. Murray JL, Zukiwski AA, Mujoo K, et al. Recombinant α interferon enhances tumor targeting of an anti-melanoma antibody in vivo. J Biol Response Mod 1990;9:556-63.
35. Khawli LA, Miller GK, Epstein AL. Effect of seven new vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumors. Cancer Suppl 1994;73:824-31.
36. Thakur ML. DeFulvio JD. Tc-99m labeled monoclonal antibodies for immunoscintigraphy. J Immunol Methods 1991; 137:217-31.
37. Pearson JW, Hedrick E, Fogler WE, et al. Enhanced therapeutic efficacy against an ovarian tumor xenograft of immunotoxins used in conjunction with recombinant α-interferon. Cancer Res 1990;50:6379-88.
38. Knop J. Immunologic effects of interferon. J Invest Dermatol 1990;95(suppl):72-4S.
39. Nakamura K, Kubo A, Hosokawa S, Nagaiki K, Hashimoto S. Effect in alpha-interferon on anti-alpha-fetoprotein-monoclonal-antibody targeting of hepatoma. Oncology 1993; 50:35-40.
40. McLeod GR. Alpha-interferons in malignant melanoma. Br J Clin Pract Suppl 1989;62:22-6.
41. Clemens MJ. Molecular mechanism of interferon action. Br J Clin Pract Suppl 1989;62:5-12.
42. Smyth JF. Guidelines for the use of Intron A (interferon-alpha-2b) in clinical oncology: lessons from the laboratory. Cancer Treat Rev 1988;15(suppl A):3-6.
43. Bergh JCS. Biological response modifiers in regional cancer therapy. Eur J Surg Suppl 1991;561:87-90.
44. Koeller JM. Biological response modifiers: the interferon alfa experience. Am J Hosp Pharm 1989;46(suppl 2):S11-5.
45. Zbinden G. Effects of recombinant human alpha-interferon in a rodent cardiotoxicity model. Toxicol Lett 1990;50:25-35.
46. Murray JL, Stuckey SE, Pillow JK, Rosenblum MG, Gutterman JU. Differentiated in vitro effects of recombinant α-interferon and recombinant γ-interferon alone or in combination on the expression of melanoma-associated surface antigens. J Biol Response Mod 1988;7:152-61.
47. Langmuir VK, Fowler JF, Knox SJ, et al. Radiobiology of radiolabeled antibody therapy as applied to tumor dosimetry. Med Phys 1993;20:601-10.